Trials / Completed
CompletedNCT00387205
Study To Assess Long Term Safety Of Pazopanib
An Open-Label, Phase Ib Study to Assess the Long Term Safety Profile of Pazopanib in Cancer Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 188 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study was a rollover study to evaluate the long term safety of pazopanib and to continue to provide pazopanib to patients who participated in a GSK sponsored pazopanib study until pazopanib is available commercially.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pazopanib | Pazopanib monotherapy or in combination with lapatinib or other approved anti-cancer medications |
Timeline
- Start date
- 2006-06-20
- Primary completion
- 2013-02-13
- Completion
- 2018-03-08
- First posted
- 2006-10-12
- Last updated
- 2019-03-06
Locations
19 sites across 4 countries: United States, France, Singapore, United Kingdom
Source: ClinicalTrials.gov record NCT00387205. Inclusion in this directory is not an endorsement.